Muntri George : I'll go along.

Mangkawat : what app this?

72749871 : How long do you think it will take OVID to rebound to $3.00? Do you think that they are setting themselves up to be bought out by a larger biopharma that doesn’t have a neurological pipeline?

Mcsnacks H Tupack : They reduced their workforce

股市捕快 : OVID announced that Takeda Pharmaceutical Company’s Phase 3 Skyline study of Soticlestat for Dravet syndrome missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy endpoints.